Arbutus Biopharma (ABUS) vs Janux Therapeutics (JANX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Arbutus Biopharma (ABUS) has outperformed Janux Therapeutics (JANX) over the past year, losing 6.7% versus a loss of 65.0%. Over five years, ABUS leads with a +28.4% price change compared with -42.9% for JANX. Janux Therapeutics is the larger company by market cap ($616.7 million vs $616.2 million), about 1.0 times the size, while Arbutus Biopharma is growing revenue faster (+128.2% vs -5.6%).
Arbutus Biopharma converts more of its revenue into profit, with a net margin of -237.9% versus -1136.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | JANX |
|---|---|---|
| Share price | $4.02 | $10.08 |
| Market cap | $616.24M | $616.73M |
| 1-day change | -1.23% | -2.04% |
| YTD return | -16.42% | -26.96% |
| 1-year return | -6.73% | -65.00% |
| 5-year return | +28.43% | -42.92% |
| P/E ratio (TTM) | 3.59 | — |
| EPS (TTM) | $1.12 | $-1.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $14.08M | $10.00M |
| Revenue growth (YoY) | +128.21% | -5.55% |
| Net income (latest FY) | $-33.50M | $-113.63M |
| Operating margin | -270.96% | -1576.67% |
| Net margin | -237.88% | -1136.25% |
| 52-week high | $5.45 | $35.34 |
| 52-week low | $3.50 | $10.05 |
| Distance from 52-week high | -26.24% | -71.48% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +32.34% | +228.77% |
| Average volume | 4.98M | 961.56K |
| Shares outstanding | 153.29M | 61.18M |
| Employees | 19 | 114 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABUS has outperformed JANX by 58.3 percentage points over the past year.
- Arbutus Biopharma is more profitable, keeping -237.9 cents of every revenue dollar as net income versus -1136.3 cents for Janux Therapeutics.
- Arbutus Biopharma grew revenue faster in its latest fiscal year (+128.21% vs -5.55%).
About Arbutus Biopharma
ABUS stock →Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Janux Therapeutics
JANX stock →Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 114 employees
ABUS vs JANX FAQ
Which is bigger, Arbutus Biopharma or Janux Therapeutics?
Janux Therapeutics (JANX) is larger, with a market capitalization of $616.73M compared with $616.24M for Arbutus Biopharma (ABUS).
Which stock has performed better over the past year, ABUS or JANX?
ABUS returned -6.73% over the past 12 months, compared with -65.00% for JANX (price return, excluding dividends). Past performance does not predict future results.
Are Arbutus Biopharma and Janux Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.